Ipatasertib
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-15186-2MG | 2 mg | 77,00 | Add | |
| HY-15186-5MG | 5 mg | 102,00 | Add | |
| HY-15186-1ML | 10mM/1mL | 104,00 | Add | |
| HY-15186-10MG | 10 mg | 140,00 | Add | |
| HY-15186-50MG | 50 mg | 380,00 | Add | |
| HY-15186-100MG | 100 mg | 584,00 | Add | |
| HY-15186-200MG | 200 mg | 964,00 | Add | |
| HY-15186-500MG | 500 mg | 1'914,00 | Add | |
| HY-15186-1G | 1 g | 3'307,00 | Add | |
| HY-15186-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Apoptosis,PI3K/Akt/mTOR,Stem Cell/Wnt |
| Format | Solubility: DMSO : 220 mg/mL (ultrasonic);H2O : 3.57 mg/mL (ultrasonic;warming;heat to 60°C) |
| Grade | Clinical information: Phase 4 |
| Purity | 99.88% |
| Molecular Formula | C24H32ClN5O2 |
| Molecular Weight | 458 |
| CAS-Number | 1001264-89-6 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
